FOXO4-DRI · Research brief

Choose FOXO4-DRI Vial Size — Research Dosing Guide

Real Peptides Research TeamEditorial

Updated July 6, 20268 min read

53 WORDS

Short answer

Key takeaways

FOXO4-DRI vial size must align with your target dose, injection route (subcutaneous vs intramuscular), and achievable reconstitution concentrations. Not arbitrary milligram preferences.
A 10mg vial reconstituted with 1mL bacteriostatic water yields 10mg/mL, delivering 5mg in a 0.5mL subcutaneous injection. The most common configuration for senolytic research.
Reconstituted FOXO4-DRI maintains potency for 28 days refrigerated at 2–8°C; larger vials suit extended protocols only if administration frequency uses the vial before degradation begins.
Subcutaneous injections should not exceed 0.5–0.7mL per site; achieving higher doses requires either splitting across sites or selecting higher concentrations through smaller reconstitution volumes.
The 20mg vial format reduces per-dose cost by 30–40% compared to 5mg vials when running multi-week protocols, but only if your timeline uses the reconstituted peptide within the 28-day stability window.

A research team ordered 10mg FOXO4-DRI vials for a multi-week senolytic protocol, reconstituted each with 2mL bacteriostatic water, and discovered halfway through that their intended 5mg dose required withdrawing 1mL per administration. Burning through vials twice as fast as budgeted and leaving no margin for dosing error. The math looked simple on paper. The execution revealed what most peptide spec sheets don't: vial size isn't about quantity alone. It's about the relationship between concentration, volume precision, and how many doses you can reliably extract before degradation becomes a variable.

Our team has guided research labs through FOXO4-DRI protocol design across three continents. The gap between choosing the right vial size and choosing the wrong one comes down to reconstitution math, injection volume tolerances, and whether your research timeline aligns with post-mixing stability windows.

How do you choose the right FOXO4-DRI vial size for research protocols?

The correct FOXO4-DRI vial size depends on your target dose per administration, injection volume capacity (typically 0.3–0.5mL subcutaneously), and protocol duration. A 10mg vial reconstituted with 2mL bacteriostatic water yields 5mg/mL concentration. Meaning a 5mg dose requires 1mL injection volume, which exceeds comfortable subcutaneous limits. Choosing vial size requires reverse-engineering from intended dose to achievable concentration, not starting with arbitrary milligram totals.

Understanding FOXO4-DRI's senolytic mechanism clarifies why vial size matters beyond convenience

FOXO4-DRI (a synthetic peptide interfering with the FOXO4-p53 interaction) selectively induces apoptosis in senescent cells by disrupting their resistance to natural cell death pathways. The peptide's efficacy in research models depends on achieving threshold plasma concentrations repeatedly across the dosing window. Senescent cell clearance isn't dose-linear, meaning underdosing due to imprecise reconstitution math produces categorically different outcomes than hitting target levels consistently.

Vial size determines reconstitution ratios, which determine concentration, which determines injection volume required to hit your target dose. If your protocol calls for 5mg administrations and you're restricted to 0.5mL subcutaneous injections, you need at least 10mg/mL concentration. Achievable only with specific vial-to-diluent ratios. A 5mg vial won't deliver that concentration without reconstituting in 0.5mL or less, which risks incomplete dissolution and creates measurement challenges with standard insulin syringes.

The peptide's structure. A 29-amino-acid sequence with a D-retro-inverso backbone modification for protease resistance. Remains stable in lyophilised form at -20°C indefinitely, but once reconstituted, degradation accelerates. Reconstituted FOXO4-DRI maintains potency for 28 days at 2–8°C under sterile conditions. Choosing vial sizes that align with your protocol's administration frequency means you're not forcing early discard of partially used vials or stretching beyond the 28-day window.

Vial size options and their practical reconstitution targets

FOXO4-DRI from Real Peptides is available in 5mg, 10mg, and 20mg lyophilised vials. The practical difference isn't just total peptide mass. It's how each size maps to achievable concentrations when mixed with standard bacteriostatic water volumes.

A 5mg vial reconstituted with 1mL bacteriostatic water yields 5mg/mL. A 0.5mL injection delivers 2.5mg. Suitable for lower-dose exploratory protocols or dose-escalation studies. Reconstituting the same vial with 0.5mL pushes concentration to 10mg/mL, allowing 5mg delivery in 0.5mL, but measuring 0.5mL diluent accurately requires precision that standard lab pipettes handle better than syringe graduations.

A 10mg vial with 2mL diluent creates 5mg/mL concentration. Delivering 5mg requires 1mL injection volume. Manageable for intramuscular protocols but outside typical subcutaneous comfort range. The same vial with 1mL diluent yields 10mg/mL, fitting 5mg into 0.5mL injections. This is the most common configuration for subcutaneous senolytic research protocols targeting 5–7.5mg per administration.

A 20mg vial offers flexibility for extended protocols or higher target doses. Reconstituted with 2mL, it yields 10mg/mL. Delivering 5mg in 0.5mL or 10mg in 1mL. For labs running multi-subject studies or dose-ranging experiments, the 20mg format reduces per-dose cost and limits the number of vials needing cold-chain storage simultaneously.

FOXO4-DRI Vial Size: Concentration and Dosing Comparison

Vial Size	Reconstitution Volume	Final Concentration	5mg Dose Volume	10mg Dose Volume	Doses Per Vial	Professional Assessment
5mg	1mL	5mg/mL	1mL (IM only)	Not achievable	1 × 5mg or 2 × 2.5mg	Best for low-dose protocols or single-administration studies
5mg	0.5mL	10mg/mL	0.5mL (SC compatible)	Not achievable	1 × 5mg	Requires precise measurement; suitable for experienced labs
10mg	2mL	5mg/mL	1mL (IM only)	2mL (not practical)	2 × 5mg	Standard for IM protocols; poor subcutaneous fit
10mg	1mL	10mg/mL	0.5mL (SC compatible)	1mL (IM compatible)	2 × 5mg or 1 × 10mg	Optimal balance for SC senolytic protocols at 5–7.5mg
20mg	2mL	10mg/mL	0.5mL (SC compatible)	1mL (IM compatible)	4 × 5mg or 2 × 10mg	Most cost-effective for extended protocols or multi-subject studies

What If: FOXO4-DRI Vial Selection Scenarios

What if your protocol requires 7.5mg doses subcutaneously?

Use a 10mg or 20mg vial reconstituted to 10mg/mL (10mg in 1mL or 20mg in 2mL). A 7.5mg dose requires 0.75mL injection volume. Manageable subcutaneously but approaching the upper comfort limit. Split into two 0.375mL injections at separate sites if patient tolerance is a concern. A 5mg vial cannot deliver 7.5mg without reconstituting in 0.67mL, which creates measurement precision issues with standard syringes.

What if you're running a dose-escalation study starting at 2.5mg?

Start with 5mg vials reconstituted with 1mL (5mg/mL concentration). A 2.5mg dose requires 0.5mL. Within easy subcutaneous range. As the protocol escalates to 5mg, switch to 10mg vials at 10mg/mL to maintain injection volume at 0.5mL. Attempting to deliver escalating doses from a single vial size forces either increasing injection volumes (patient discomfort) or frequent reconstitution ratio changes (introduces variability).

What if your storage capacity limits how many reconstituted vials you can refrigerate simultaneously?

Choose 20mg vials. A single 20mg vial reconstituted to 10mg/mL provides four 5mg doses or two 10mg doses, reducing the number of open vials requiring refrigerated space. For research labs with limited pharmaceutical-grade cold storage, fewer high-concentration vials outperform multiple low-dose vials logistically. The tradeoff is upfront cost. 20mg vials require larger initial capital outlay but lower per-administration cost over the protocol's duration.

The Unvarnished Truth About FOXO4-DRI Vial Sizing

Here's the honest answer: most researchers choose FOXO4-DRI vial size by guessing at total milligrams needed without calculating concentration and injection volume first. That's backwards. The correct sequence is: decide your per-dose target (e.g. 5mg), determine your injection volume limit (subcutaneous = 0.5mL max comfortably), calculate required concentration (10mg/mL), then reverse-engineer which vial size and reconstitution volume delivers that concentration. A 10mg vial with 1mL diluent is the default for good reason. It hits 5mg in 0.5mL, uses standard bacteriostatic water volumes, and fits insulin syringe graduations without guesswork.

Reconstitution precision and measurement tools matter as much as vial selection

Choosing the right FOXO4-DRI vial size solves half the equation. The other half is accurate reconstitution and dose withdrawal. Bacteriostatic water should be added slowly down the vial wall, never directly onto the lyophilised powder, to prevent foaming and protein denaturation. Once mixed, gently swirl. Never shake. Until fully dissolved. Vigorous agitation breaks peptide bonds.

Standard 1mL insulin syringes with 0.01mL graduations are suitable for withdrawing doses from 5mg/mL or 10mg/mL concentrations. For higher concentrations requiring smaller volumes (e.g. 0.2mL from 25mg/mL), laboratory-grade glass syringes or Hamilton syringes with finer graduations reduce measurement error. A 5% volume measurement error at 0.5mL equals 0.025mL. Translating to 0.25mg dose variance at 10mg/mL concentration, which is within acceptable research tolerances. The same 5% error at 0.1mL doses (10% relative error) pushes outside acceptable limits for dose-response studies.

Every vial withdrawal introduces air into the remaining solution. Compounding contamination risk over multiple draws. Draw the full reconstituted volume into a sterile syringe, then aliquot into individual sterile vials if your protocol spans multiple administrations. This approach limits the primary vial to a single puncture, reducing degradation from repeated needle access. For research exploring combinations like the FAT Loss Stack or FAT Loss Metabolic Health Bundle, understanding peptide handling fundamentals like this ensures reliable outcomes across multi-compound protocols.

Vials should never reach room temperature during storage. Lyophilised peptides tolerate brief ambient exposure (under 24 hours at 25°C), but reconstituted solutions degrade rapidly above 8°C. Refrigerated storage at 2–8°C is non-negotiable post-mixing. Any temperature excursion. Shipping delays, power outages, leaving vials on the bench during dose prep. Starts irreversible degradation that no appearance check or potency assay at home can detect.

If your protocol requires administrations at intervals longer than 28 days apart, smaller vials that get used completely within the stability window outperform larger vials held past the degradation threshold. A 5mg vial used entirely in week one beats a 20mg vial with 15mg remaining in week five. The latter's remaining peptide has spent a month in aqueous solution losing potency incrementally. When exploring emerging research compounds or examining metabolic pathways studied with tools like the Energy Mitochondria Fatigue Bundle, matching vial size to actual use windows prevents waste and maintains consistent concentrations.

Choose FOXO4-DRI vial size by working backward from your target: identify dose per administration, map concentration needed for comfortable injection volumes, calculate which vial-to-diluent ratio delivers that concentration, then select the vial size that fits your protocol's frequency and duration without forcing discard or stretching past stability limits. The vial isn't the product. The reconstituted peptide is, and everything upstream of that moment determines whether your research hits its mark or drifts into approximation.

All compounds discussed on this page are sold for research use only and are not for human consumption.

References

Peer-reviewed sources on FOXO4-DRI indexed in PubMed, listed for research context. Real Peptides supplies FOXO4-DRI for laboratory research use only.

Targeting the FOXO4-p53 axis by retro-inverso peptide senolytic agents: a pharmacological strategy to mitigate brain aging and cognitive decline. Naunyn-Schmiedeberg's archives of pharmacology, 2026. PMID 42024235. doi:10.1007/s00210-026-05309-6
FOXO4 as a Redox-Sensitive Regulator of Antioxidant Defense and Cellular Senescence: Cysteine-Based Signaling, p53 Interaction, and Therapeutic Targeting. Antioxidants (Basel, Switzerland), 2026. PMID 42510573. doi:10.3390/antiox15070842
FOXO4-DRI induces keloid senescent fibroblast apoptosis by promoting nuclear exclusion of upregulated p53-serine 15 phosphorylation. Communications biology, 2025. PMID 39994346. doi:10.1038/s42003-025-07738-0
The disordered p53 transactivation domain is the target of FOXO4 and the senolytic compound FOXO4-DRI. Nature communications, 2025. PMID 40593617. doi:10.1038/s41467-025-60844-9
FOXO4-DRI regulates endothelial cell senescence via the P53 signaling pathway. Frontiers in bioengineering and biotechnology, 2025. PMID 41625068. doi:10.3389/fbioe.2025.1729166
FOXO4-DRI improves spermatogenesis in aged mice through reducing senescence-associated secretory phenotype secretion from Leydig cells. Experimental gerontology, 2024. PMID 39025385. doi:10.1016/j.exger.2024.112522
FOXO4-D-Retro-Inverso targets extracellular matrix production in fibroblasts and ameliorates bleomycin-induced pulmonary fibrosis in mice. Naunyn-Schmiedeberg's archives of pharmacology, 2023. PMID 37074394. doi:10.1007/s00210-023-02452-2
FOXO4 peptide targets myofibroblast ameliorates bleomycin-induced pulmonary fibrosis in mice through ECM-receptor interaction pathway. Journal of cellular and molecular medicine, 2022. PMID 35510614. doi:10.1111/jcmm.17333

Build a pack

Researching more than one compound?

Build a multi-vial pack and the discount applies automatically as you add doses.

Start a pack

Questions

The 10mg vial is the most common standard for senolytic research protocols. When reconstituted with 1mL bacteriostatic water, it yields 10mg/mL concentration — allowing 5mg doses to be delivered in 0.5mL subcutaneous injections, which fits within comfortable injection volume limits and uses the vial completely in two administrations within the 28-day post-reconstitution stability window.

Yes, but reconstitution becomes critical. A 5mg vial must be reconstituted with 0.5mL bacteriostatic water to achieve 10mg/mL concentration, allowing the full 5mg dose in 0.5mL. Reconstituting with 1mL yields only 5mg/mL, requiring a 1mL injection — acceptable intramuscularly but uncomfortable and impractical for subcutaneous administration.

Reconstituted FOXO4-DRI maintains potency for 28 days when stored at 2–8°C under sterile conditions. Beyond this window, peptide degradation accelerates even with proper refrigeration. Choosing vial sizes that align with administration frequency ensures the peptide is used before degradation becomes a research variable — vial selection isn't just about total milligrams but about matching dose count to the stability timeline.

For subcutaneous protocols, target 10mg/mL concentration. This allows 5mg doses in 0.5mL injections — the upper practical limit for comfortable subcutaneous administration. Achieving 10mg/mL requires either a 10mg vial with 1mL diluent or a 20mg vial with 2mL diluent. Lower concentrations force larger injection volumes; higher concentrations require measurement precision beyond standard insulin syringe graduations.

Yes, if your protocol uses all 20mg within 28 days post-reconstitution. The per-milligram cost drops 30–40% compared to 5mg vials, and fewer vials reduce cold storage demands and reconstitution labour. However, if your administration schedule only requires 10mg over the 28-day window, the remaining 10mg degrades unused — making the 20mg vial wasteful rather than economical.

Choose the next-larger vial size and reconstitute to achieve the concentration that fits your target dose in a manageable injection volume. For example, a 7.5mg dose protocol works with a 10mg or 20mg vial reconstituted to 10mg/mL (requiring 0.75mL injection). Attempting to achieve non-standard doses from undersized vials forces either impractical reconstitution volumes or injection volumes outside subcutaneous tolerances.

Subcutaneous injections limit comfortable volume to 0.5–0.7mL per site, requiring higher concentrations (10mg/mL or above) to deliver therapeutic doses without splitting across multiple injection sites. Intramuscular protocols tolerate 1–2mL volumes, allowing lower concentrations (5mg/mL). Vial size choice depends on achieving the concentration your injection route requires — subcutaneous protocols need vial-to-diluent ratios that produce at least 10mg/mL.

Base it on per-administration dose first, then verify total protocol demand fits the 28-day post-reconstitution stability window. If your protocol runs 8 weeks with weekly 5mg administrations, you need 40mg total — but you cannot reconstitute a 40mg vial and use it across two months. Instead, use four 10mg vials, reconstituting each fresh to serve two administrations within 28 days. Vial size serves stability timelines, not arbitrary bulk purchasing.

Yes, provided you aliquot the reconstituted solution into individual sterile vials immediately after mixing to prevent repeated needle punctures of the primary vial. Each withdrawal introduces contamination risk and air exposure. For multi-subject studies, 20mg vials reconstituted and aliquoted into four 5mg doses (each in 0.5mL) reduce per-subject cost while maintaining sterility and dose accuracy across all subjects.

Choosing undersized vials forces either impractically small reconstitution volumes (measurement error risk) or injection volumes too large for the intended route. Choosing oversized vials leads to waste — unused peptide degrading past the 28-day stability window before the protocol finishes. Neither scenario is recoverable mid-protocol without ordering new vials and restarting, making upfront vial size calculation critical to research continuity and budget adherence.

RESEARCH USE ONLY · NOT EVALUATED BY THE FDA